Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations

“…However, the results of the ADL analysis are in accordance with previous studies which reported significant improvements of the same magnitude (2.3 point improvement in the present study) with entacapone (10)(11)(12)(13). A two-point improvement in Table 3 The most frequently reported adverse events (AEs) (>5% incidence in the entacapone group) ADL scores is generally considered clinically relevant (18) and would have been expected to be also significant in the ADL subscale of the PDQ-39.…”

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations

“…However, the results of the ADL analysis are in accordance with previous studies which reported significant improvements of the same magnitude (2.3 point improvement in the present study) with entacapone (10)(11)(12)(13). A two-point improvement in Table 3 The most frequently reported adverse events (AEs) (>5% incidence in the entacapone group) ADL scores is generally considered clinically relevant (18) and would have been expected to be also significant in the ADL subscale of the PDQ-39.…”

Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention

“…We have also found a significant increase of 1.5 h in the mean daily ‘on’ time, in keeping with results of previous studies using home diaries that reflected an average increase of 1–2 h, with a corresponding reduction in ‘off’ time, in patients with PD with motor fluctuations [12,14]. Moreover, we have found an improvement in the motor score of the UPDRS since the third month of treatment, in contrast with results of a recent clinical trial [27] in which there was no difference between entacapone and placebo for that UPDRS subscale. This study included both fluctuating and non‐fluctuating patients.…”

Placebo‐controlled, double‐blind dose‐finding study of entacapone in fluctuating parkinsonian patients

“…No neuroleptic malignant syndrome or severe hepatic disorders were observed in the entacapone groups. Overall, the good safety and tolerability profile seen in previous entacapone studies8, 9, 11, 12 was confirmed here.…”

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations

“…However, the results of the ADL analysis are in accordance with previous studies which reported significant improvements of the same magnitude (2.3 point improvement in the present study) with entacapone (10)(11)(12)(13). A two-point improvement in Table 3 The most frequently reported adverse events (AEs) (>5% incidence in the entacapone group) ADL scores is generally considered clinically relevant (18) and would have been expected to be also significant in the ADL subscale of the PDQ-39.…”

Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention

“…We have also found a significant increase of 1.5 h in the mean daily ‘on’ time, in keeping with results of previous studies using home diaries that reflected an average increase of 1–2 h, with a corresponding reduction in ‘off’ time, in patients with PD with motor fluctuations [12,14]. Moreover, we have found an improvement in the motor score of the UPDRS since the third month of treatment, in contrast with results of a recent clinical trial [27] in which there was no difference between entacapone and placebo for that UPDRS subscale. This study included both fluctuating and non‐fluctuating patients.…”

Placebo‐controlled, double‐blind dose‐finding study of entacapone in fluctuating parkinsonian patients

“…No neuroleptic malignant syndrome or severe hepatic disorders were observed in the entacapone groups. Overall, the good safety and tolerability profile seen in previous entacapone studies8, 9, 11, 12 was confirmed here.…”

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations

“…However, the results of the ADL analysis are in accordance with previous studies which reported significant improvements of the same magnitude (2.3 point improvement in the present study) with entacapone (10)(11)(12)(13). A two-point improvement in Table 3 The most frequently reported adverse events (AEs) (>5% incidence in the entacapone group) ADL scores is generally considered clinically relevant (18) and would have been expected to be also significant in the ADL subscale of the PDQ-39.…”

Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention

“…We have also found a significant increase of 1.5 h in the mean daily ‘on’ time, in keeping with results of previous studies using home diaries that reflected an average increase of 1–2 h, with a corresponding reduction in ‘off’ time, in patients with PD with motor fluctuations [12,14]. Moreover, we have found an improvement in the motor score of the UPDRS since the third month of treatment, in contrast with results of a recent clinical trial [27] in which there was no difference between entacapone and placebo for that UPDRS subscale. This study included both fluctuating and non‐fluctuating patients.…”

Placebo‐controlled, double‐blind dose‐finding study of entacapone in fluctuating parkinsonian patients

“…No neuroleptic malignant syndrome or severe hepatic disorders were observed in the entacapone groups. Overall, the good safety and tolerability profile seen in previous entacapone studies8, 9, 11, 12 was confirmed here.…”